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ABSTRACT
Background : We  compared  the efficacy of
oral antibiotics with intravenous antibiotics
in low risk febrile neutropenia.
Design : A prospective,  randomized study
Methods: Between April 2004 - December
2005, 55 patients  with  low risk febrile
neutropenia  (expected neutropenia  duration
< 7 days with no co-morbid features)  between
15 and 75 years of age,  were randomized to
receive either oral amoxicillin-clavulanate
625mg twice daily and levofloxacin -500mg
once daily OR intravenous (i.v.) ceftriaxone 2g
and amikacin 15mg/kg once daily.  Most
patients were treated on out patient basis. The
primary end point was response to therapy,
defervescence  of  fever within 72 hours with
improvement in any clinical manifestation of
infection and  no recurrence of fever for 48
hours without use of antipyretics. Use of
growth factors was not permitted except in
treatment failure.
Results:  A  total of 64 febrile episodes were
recorded (mean  1.20 );   33 in the IV  group
and 31 in the oral antibiotics group. Both
groups were equally matched for age (median
25 years in the IV group and 19 years in the
oral group), gender, type of  cancer, baseline
absolute neutrophil count (median 200/cmm
in both arms) and duration of neutropenia (5
days and 4 days in the IV and oral groups,
respectively). A focus of infection was
identified clinically in 15% of episodes and
microbiologically in 11% of episodes; 57% of
which were Gram positive organisms and the
rest Gram negative. 72% in the IV arm and
77% in the oral arm responded to therapy
(p=ns). One patient in IV group had one
episode of seizure. Non-responding patients
received  second line IV antibiotics. There was
no mortality in either group. Age > 60 years,
neutropenia lasting > 7 days after the onset
of fever and positive blood culture were
predictors  for lack of response to antibiotics
on multivariate analysis.
Conclusion: Oral antibiotics have comparable
efficacy as IV antibiotics in the management
of low risk febrile neutropenia.
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INTRODUCTION
Neutropenic fever following anticancer
chemotherapy is a medical emergency and
requires immediate admission and empiric broad
spectrum intravenous antibiotics.  In the past few
years several authors have attempted to stratify
these febrile neutropenic patients into low and
high risk based on  expected duration of
neutropenia  and presence of  co-morbid factors.
This has led to the emergence of a category called
‘low risk febrile neutropenia’1-9 - associated with a
low incidence of serious complications.  Oral
antibiotics have been  proposed as a treatment
option this subgroup due to ease of administration
on outpatient basis,  reduced risk of  complications
associated with  IV  access and  nosocomial
infections  could be prevented.  Several studies10-15
and a meta analysis16 have shown that oral
antibiotics are as safe and effective as IV
antibiotics in low risk febrile neutropenia.
However, this strategy has not been adequately
tested in developing countries. On one hand in
these countries there is a paucity of resources
hence oral antibiotics may help avoid   in-patient
admissions. At the same time the issues of patient
compliance to therapy, periodic monitoring and
access to admission in case of clinical deterioration
need to be looked at.  Hence we felt the need for a
randomized study to compare the efficacy of oral
and IV antibiotics in our setting.
PATIENTS AND METHODS
Patient  of age group 15 to 75 years, with
chemotherapy induced febrile neutropenia and
with low risk  features were included in the study
after a written informed consent.
Febrile Neutropenia   was defined as a  single
oral temperature recording of 38.3
o
C (101
o
F) or
temperature of 38
o
 C (100.4
o
F) for 1 hour unrelated
to administration of drug or blood products and
absolute neutrophil count (ANC) < 500 cells / cmm.
Patients were defined to have ‘low risk features’ if
(i) expected duration of neutropenia was 7 days or
less after the onset of fever (ii) with absence of co-
morbid features e.g. (a) Hypotension : systolic B.P.
less than 90 mm Hg  (b) Hepatic Dysfunction: 1)
amino-transferases >5 times  from  baseline 2)
Serum bilirubin = 3mg/dl (c) Renal Dysfunction:-
Creatinine clearance <30ml/min (d) Diabetes
Mellitus (e) altered sensorium (f) respiratory
insufficiency.  Exclusion criteria included –
pregnancy,  lactation,  known hypersensitivity to
any of the study drugs, patient’s inability to take
oral medication due the mucositis (grade III-IV)
and vomiting (grade III-IV). Patients who had
received antibiotics for any reason within previous
96 hours were excluded.    Patients with acute
myeloid leukemia (AML), acute lymphoblastic
leukemia (ALL) ,lymphoblastic lymphoma,
Burkitt’s lymphoma on induction and
consolidation chemotherapy were considered high
risk and were are not included in the study.
METHODOLOGY
All patients underwent complete evaluation at the
time of enrollment. This included - a detailed
physical examination (to ascertain the possible
focus of infection), complete blood counts (total
and differential) and chest x-ray. Blood sugar, renal
and liver function test , electrolytes were done at
base line.  Blood culture ( two sets) , throat swab ,
urine culture, and cultures from other sites (as
clinically indicated) were done in all patients.  An
informed written consent was taken from the
patient or guardian at the time of enrollment. The
study protocol was approved by the institution
ethics committee.
Patients were randomized by a computer
generated randomization table into two groups 
Group I patients received: Inj Ceftriaxone 2g
intravenously q once daily  and Inj Amikacin 15
mg/kg intravenously once daily. Group II patients
received : Tab Amoxycillin 500mg + Clavulinic
acid 125 mg (15mg/kg Amoxycillin) orally twice
daily after food and Tab Levofloxacin 500mg orally
once daily after food.
Use of antacids, iron preparations, oral
calcium and magnesium supplement was not
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allowed 2 hours before and after administration of
the study drugs. Concomitant use of theophylline
derivatives and probenecid was not permitted.
FOLLOW UP
Patients who were admitted were monitored daily.
Patients who were in the oral antibiotic group were
followed on outpatient basis on alternate day till
absolute neutrophil count (ANC) was >500 cells/
cmm.  Patients were instructed to record oral
temperature at home at least 4 times daily and
bring the record of the temperature chart . If fever
was  persistent blood and other appropriate
cultures were repeated. Blood counts  and serum
chemistries were performed every alternate day.
The dose of  amikacin  was modified as per
creatinine clearance.
Response: Response to treatment was defined as
resolution of temperature within 72 hours of
starting therapy and  lasting for at least 48 hours
without antipyretics . Resolution / improvement
in the symptoms and signs of infection at
identifiable sites of infection was recorded.
Treatment Failure was defined as  (i) lack of
defervescence of fever after 72 hours of therapy (ii)
If there was clinical  progression in any of the
documented sites of infection (iii) if patient
developed hypotension, respiratory insufficiency,
altered sensorium, renal failure (due to sepsis),
hepatic dysfunction at any point after entry into
the study. The time to respond to therapy, salvage
antibiotic regimens used and complications of
therapy were analyzed as secondary endpoints.
Further Therapy: If the patient responded to
therapy the same antibiotics were continued for 3-
4 days of  the afebrile period or till the absolute
neutrophil count (ANC was >500) cells/cmm  for
two consecutive days,  whichever was earlier.
STATISTICAL ANALYSIS
The study was essentially a pilot study to test the
feasibility of using oral antibiotics in febrile
neutropenia in our hospital  setting.   The Chi
Square test and Fischer’s exact test were used to
compare differences between the groups.
Nonparametric tests were used for comparison
when the data was not normally distributed.
Logistic regression was used for multivariate
analysis of outcome. All p values were two-sided.
All statistical calculations were performed using
SPSS Software  version 10.
RESULTS
Among 55 patients randomized  in this study; 53
were evaluable, one patient withdrew the consent
and another belonged to high risk febrile
neutropenia. A total of 68 febrile episodes were
recorded; IV arm – 35 and oral arm -33. Patients
characteristics are shown in table-1.
FOCUS OF INFECTION
Clinically and radiologically - site of infection
could be identified in 10/64 episodes (15%). Chest
– 5, (Clinical - 3, X-ray chest abnormality - 2) all in
intravenous group. GIT- 4 episodes (2 in the IV  and
2 in the oral group). Skin furuncles in 1 patient
(oral group). Preseptal cellulitis of the eyeball in 1
episode (oral group).  Eight of 33 (24%)  febrile
episodes in the IV group and 7 of 31 (23%) episodes
in the oral group were associated with grade 1 and
2 oral mucositis.  Microbiologically culture
positivity could be demonstrated in seven episodes
(10%) either in blood or urine. as outlined in Table
3. Gram positive organisms accounted for 53%
and the rest were gram negative. In one episode
two organisms were grown from blood culture.
RESPONSE TO THERAPY
24 out of 33 episodes (72%) in the IV group and 24
out of  31 (77% ) in oral group responded to therapy.
Testing the two groups for equivalence (assuming
a 25% difference between the two groups as
unequal) the two groups were equivalent with a
power of 59%. (p = 0.03).  19 out of  28  first
episodes in the intravenous group (68%) and 21 out
of 25 first episodes in the oral group  responded to
therapy. (84%).  The time to become afebrile from
the start of therapy was calculated from the
temperature diary maintained by the patients or
from the hospital temperature charts. Table 4
shows that it was similar in both groups.
INDIAN JOURNAL OF MEDICAL & PAEDIATRIC ONCOLOGY Vol. 28 No 2, 2007 10
Toxicity : The details of adverse effect of
treatment are given in table 7. There was no
mortality in any group. In the IV group one patient
had one episodes of generalized tonic clonic
seizures during primary therapy; CAT scan  of  the
head was normal, and  patient  was found to have
hypocalcemia. The patient recovered without any
sequelae. 2 patients in the IV group had evidence
of  thrombo-phlebitis and 3 patients in the oral
group had diarrhoea  considered related  to
antibiotics. Change or modification of antibiotics
was not required in any patient due to side effects
or abnormal liver or renal function.
DISCUSSION
Oral antibiotics are a feasible option in low risk
febrile neutropenia   The commonly used
combination is amoxycillin - clavulanate with a
quinolone which has been adhered to in this study.
Levofloxacin was preferred to ciprofloxacin due to
convenience of  once daily dose administration and
a broader gram  positive coverage.17 The culture
reports revealed a high incidence of ESBL
positivity among the gram negative organisms (3
out of 4). This justifies the need for a beta
lactamase inhibitor in the antibiotic combination.
We used a 72 hour time period for  primary  end
point assessment, as the median time to respond
to antibiotics in low risk febrile neutropenia is 2
days.  Broadly the study follows the International
guidelines for the design and analysis at studies on
febrile neutropenia18 except for the method of risk
stratification. The MASCC system4 of risk
stratification was avoided as we felt that stratifying
patients using a visual analog scale was not always
reproducible. Retrospectively scoring patients by
the MASCC score revealed 94% patients had a
score of > 21 (low-risk) but retrospective scoring
Table  -1 Patients’s  Characteristics
Characteristics IV Antibiotic Oral Antibiotic p value
Group Group
Age - Median (range) in years 25 (15-73) 19 (15-64) 0.209
Gender (M:F) 2.6:1 1.2:1 0.136
Hemoglobin (g/dl) - Median (range) 8.2 (3.5 - 13.3) 8.6 (4.5 - 12.9) 0.437
Platelet (cells/cmm) Baseline Median (range) 86000 87000 0,587
ANC (baseline) (cells/cmm) Median (range) 200 (0 - 400) 200 (0 - 400) 0.448
Duration of neutropenia (Days) Median (range) 5 (2 - 17) 4 (2 - 11) 0.223
Number of patients treated as Outpatients 21 29  
Diagnosis
Haematological malignancies* 13 8
Bone & Soft tissue sarcomas 14 18
Other solid tumours 6 5
IV group–non Hodgkin’s lymphoma-6, Hodgkins lymphoma-2, CML-1, ALL-4, Oral group-NHL-6, ALL-2
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Table - 2 :     TYPE OF CHEMOTHERAPY
Type of Chemotherapy Intravenous Antibiotic Oral Antibiotic
Group (# episodes) Group (# episodes)
CHOP 6 4
Ifosfamide + etoposide 3 7
VAC 3 5
VAC- RMS 2 2
ALL maintenance (MCP-841) 2 2
ALL C phase (MCP-841) 1 0
ICE 2 0
R CHOP 0 1
Imatinib 1 0
BEP 1 1
HDMTX 1 1
Cisplatin + adriamycin 5 5
Cisplatin + Etoposide 2 0
CAP 1 1
Carboplatin 1 0
EMACO 1 0
ABVD 1 0
+ Ifosfamide +Adria mycin 0 1
Folfox 4 0 1
CHOP- cyclophosphamide, adriamycin, vincristine and prednisolone, ABVD- adriamycin, bleomycin, vinblastine and DTIC,
CAP-cisplatin, acriamycin and cyclophosphamide, EMA-CO – etoposide, methotrexate and actinomycin-D, cyclophosphamide
and vincristine, BEP-bleomycin, etoposide and cisplatin, HDMTX-high dose methotrexate.
has its own limitations. Risk stratification in this
study was based on duration of neutropenia and
the presence or absence of co-morbid features.
Based on these criteria for risk stratification, there
was no mortality and the incidence of serious
complications was about 8%  which is acceptable.
A major criticism of  the use of expected duration
of neutropenia for risk stratification is that it may
not accurately predict the actual duration but in
91% of  patients we did not encounter this
problem. However,  as we discovered during the
course of this study certain clinical situations such
as imatinib induced myelosupression may have
prolonged neutropenia (17 days for the patient in
this study) and may not be suitable for low risk
therapy.  The response rates to both oral and
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 Table 3 : Microbiology Spectrum
Group Sample Organism Sensitive to Resistant to End point
Intravenous Urine Escherichia Cefaperazone sulbactum Ceftriaxone, amikacin, Failure
Coli ESBL* amoxiclav, levoflox
Positive
Intravenous Blood (MSSA) Ceftriaxone, amikacin, amoxiclav, Levofloxacin Failure
cefaperazone sulbactum
Intravenous Blood Coagulase amikacin, levofloxacin, Ceftriaxone, augmentin Responded
negative cloxacillin
Staphylococcus
Acinetobacter Amikacin, Imipenem, Ceftriaxone, amoxiclav,
levoflox
Oral Blood Pseudomonas Piperacillin, Piperacillin Ceftriaxone, amikacin, Responded
ESBL* tazobactum amoxiclav, levoflox
positive
Oral Blood Enterococcus Vancomycin, teicoplanin, linezolid Ceftriaxone, amikacin, Failure
faecium amoxiclav, levoflox
Oral Blood Coagulase Ceftriaxone, amikacin, amoxiclav, Penicillin erythromycin Responded
negative levoflox
Staphylococcus
Oral Blood Acinetobacter Levofloxacin, Amikacin, amoxiclav, Ceftriaxone Failure
ESBL*
Positive
ESBL-Extended spectrum beta lactamase, MSSA- Methicillin sensitive Staphylococcus aureus
intravenous antibiotics in the present study are
similar to what was obtained in earlier randomized
studies as illustrated in Table 9.
The study was not designed to establish the
equivalence of  outpatient and inpatient therapy.
However since 50 out of 64 episodes in the study
were treated on outpatient basis this approach can
be considered a feasible option. Patients must be
instructed carefully to follow up at least every third
day on outpatient basis, to reside near the hospital
and report to the casualty in case of  any emergency.
Maintaining daily telephonic contact with
patients, which was part of the protocol in some
Western studies 21 may not be practical for our
patients.
A cost analysis was not performed as part of
this study. However, the approximate daily cost of
oral antibiotics used in this study was Rs. 100/-
and that of  intravenous antibiotics. Rs. 225/-.
Further use of oral antibiotics is cost effective as
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TABLE 4 : TIME TO RESPONSE  TO ANTIBIOTICS
Time to respond Intravenous Antibiotic Group Oral  Antibiotic Group
< 24 hrs 7 (29 %) 5 (21%)
24 to 48 hrs 8 (33%) 9 (38%)
48- 72 hrs 9 (38%) 10 (41%)
TABLE 5 : REASONS FOR FAILURE
Reason Intravenous Antibiotic Oral Antibiotic  Group
Group (# of episodes) (# of  episodes)
No response within 72 hours of 6/9 5/7
therapy
Clinical deterioration 2/9 2/7
Breakthrough fever after 1/9 0/7
response
TABLE 6 : SECOND LINE TREATMENT
Intervention Intravenous Antibiotic Group Oral Antibiotic Group
(no of episodes) (no of episodes)
Addition of antibiotic 1 0
Continuation of same 1 0
antibiotic
Second line antibiotics 7, Cefaperazone + sulbactum 7 Ceftriaxone -6  
in all patients Cefaperazone + sulbactum 1
Vancomycin - 1
Third line antibiotics 0 1 - Cefaperazone sulbactum
Growth factors 0 3
the transportation and hospitalization charges can
be avoided. The limitations of  this study area small
sample size, (a power of  80% would have been
ideal), lack of  stratified randomization strategy,
which could have permitted a subgroup analysis
and the heterogeneity in admission of patients.
This study could be a model for more studies on
this topic with more number of patients and
different antibiotic combinations.
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TABLE-7 : PROGNOSTIC FACTORS
Variable Univariate Multivariate Odds ratio ( 95% C.I.)
p value p value
Age < 60 .045 .046 10.846(1.040 to 113.165)
Age < 50 .401
Clinical focus of  infection .099
Hb < 8g/dl .769
ANC 100 baseline .657
ANC 100 nadir .451
Duration of neutropenia .007 .018 10.098 (1.494 to 68.267)
> 7 days
Culture positivity .059 .038 6.659 (1.112 to 39.865)
Hospitalization status .031 .232 2.55 (0.549 to 11.846)
TABLE 8 :  REVIEW OF LITERATURE
Study (ref), year Response to IV antibiotics Response to oral
antibiotics
Malik (14) 1992 53% 53%
Rubenstein (13)1993 95% 87.5%
Velasco (19) 1995 93% 94%
Hidalgo (20) 1999 87% 79%
Freifield (10) 1999 59% 70%
Kern (11) 1999 84% 85%
Innes (21) 2003 90% 84%
Present study 72% 77%
Factors responsible for failure to respond to antibiotics in both groups were studied. Prognostic factors : Age 60 years and
above, duration of neutropenia >7 days from randomization and a positive culture during the episode emerged as significant
prognostic factors on multivariate analysis (Table-7)
Acknowledgements
We gratefully acknowledge help of  Dr. Rajvir
Singh and Ms Kalaiwani of Bio-statisctics
Department, AIIMS, New Delhi  for statistical
analysis. We also appreciate the help of   Medical
representatives from Glaxo-Smithkline, Ranbaxy &
Aventis pharmaceuticals for providing free
samples of  antibiotics for this study.
INDIAN JOURNAL OF MEDICAL & PAEDIATRIC ONCOLOGY Vol. 28 No 2, 2007 15
REFERENCES:
1. Rubin M, Hathorn JW, Pizzo PA. Controversies in the
management of febrile neutropenic cancer patients.
Cancer Invest 1988;6-167.
2. Talcott JA, Finberg R, Mayer RJ, Goldman L. The
medical course of cancer patients with fever and
neutropenia. Clinical identification of a low-risk
subgroup at presentation. Arch Intern Med 1988;148-2561
3. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk
assessment in cancer patients with fever and neutropenia:
a prospective, two-center validation of a prediction rule.
J Clin Oncol 1992;10-316.
4. Klasterky J, Paesman M, Rubenstein EB et al . The
multinational association for supportive care in cancer
risk index: a multinational scoring system for identifying
low risk febrile neutropenia .  J.Clin Oncology 2000;18
:3038-51.
5. Rolston KVI. New trends in patient management: risk-
based therapy for febrile patients with neutropenia. Clin
Infect Dis 1999;29:515-21.
6. Aquino VM, Tkaczewski I, Buchanan GR. Early discharge
of low-risk febrile neutropenic children and adolescents
with cancer. Clin infect Dis 1997;25:74-8.
7. Klaasseen RJ, Goodman R, Pham BA, Doyle JJ. Low-risk
prediction rule for pediatric oncology patients presenting
with fever and neutropenia. J Clin Oncol 2000;18:1012-9.
8. Lucas KG ,Brown AE, Armstrong D et al. The
identification of febrile neutropenic children with low
risk for bacteremia and complications of sepsis. Cancer
1996;77:791-798.
9. Kern WV, Cometta A, DeBock R, et al. Oral versus
intravenous empirical antimicrobial therapy for fever
in patients with granulocytopenia who are receiving
cancer chemotherapy. N Engl J Med 1999;341:312-8
10. Freifeld A, Marchigiani D, Walsh T, et al. A double-blind
comparison of  empirical oral and intravenous antibiotic
therapy for low-risk febrile patients with neutropenia
during cancer chemotherapy. N Engl J Med 1999;341:305-
11.
11. Rackoff WR,Gonin R, Robinson C et al . Predicting the
risk of bacteremia in children with fever and
neutropenia. J Clin Oncology 1996;14:919-924.
12. Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R.
Home antibiotic therapy for low-risk cancer patients
with fever and neutropenia: a pilot study of 30 patients
based on a validated prediction rule. J Clin Oncol 1994;12-
107. 
13. Rubenstein EB, Rolston K, Benjamin RS, et al. Outpatient
treatment of febrile episodes in low-risk neutropenic
patients with cancer. Cancer 1993;71-3640.
14. Malik IA, Abbas Z, Karim M. Randomised comparison
of oral ofloxacin alone with combination of parenteral
antibiotics in neutropenic febrile patients [published
erratum appears in Lancet 1992; 340(8811):128]. Lancet
1992;339-1092.
15. Malik IA, Khan WA, Karim M, Aziz Z, Khan MA.
Feasibility of outpatient management of fever in cancer
patients with low-risk neutropenia: results of a
prospective randomized trial Am J Med 1995;98-224.
16. Liat Vidal, Mical Paul, Istik Ben dor,Karla Soares-
Weiser,Leonard Leibovici. Oral versus intravenous
antibiotic treatment for febrile neutropenia in cancer
patients: a systematic review and meta-analysis of
randomized trials.  J  Antimicrobial Chemotherapy
2004;54-29.
17. Fu KP, Lafredo SC, Foleno B, et al. In vitro and in vivo
antibacterial activities of levofloxacin, an optically
active ofloxacin. Antimicrob Agents Chemother 1992;36-
860.
18. Feld R, Paesmans M, Freifeld AG, et al. Methodology
for clinical trails involving patients with cancer who
have febrile neutropenia: updated guidelnies of  the
Immuno-compromised Host Society / Multinational
Association for Supportive Care in Cancer with
emphasis on outpatients studies. Clin Infectious Dis
2002;35:1463-8.
19. Velasco E, Costa MA, Martins CA, et al. Randomized
trial comparing oral ciprofloxacin plus penicillin V with
amikacin plus carbenicillin or ceftazidime for empirical
treatment of febrile neuropenic cancer patients. Am J
Clin Oncol  Cancer Clin Trials 1995;18:429-35.
20. Hidalgo M, Homedo J, Lumbreras C, et al. Out patient
therapy with oral ofloxacin for patients with low risk
Neutropenia and fever a prospective, randomized
clinical trial. Cancer 1999;85:213-9.
21. Innes HE, Smith DB, O’  Reilly SM, et al. Oral
antibiotics with early hospital discharge compared with
in patient intravenous antibiotics for low-risk febrile
Neutropenia in patients with cancer: a prospective
randomized controlled single center study. Br J Cancer
2003;89:43-9.
22. Elting LS Rubenstein EB Rolston K et al. Time to clinical
response : an outcome of antibiotic therapy of febrile
neutropenia with implications for quality and cost of
care. J Clin Oncol 2000;18:3699-3706.

